ArticleFrontiers in neurology2019
Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease.
Article in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Analysis of α-synuclein seed amplification assay in carriers ofJournal of Parkinson's disease · 2026Article
- Genetic Modifiers of Parkinson's Disease: A Case-Control Study.Annals of clinical and translational neurology · 2025Observational
- Impact of LRRK2 and GBA variants on orthostatic hypotension in patients with Parkinson's disease.Journal of neurology · 2025Article
- Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers.European journal of neurology · 2024Article
- Associations of cholinergic system integrity with cognitive decline in GBA1 and LRRK2 mutation carriers.NPJ Parkinson's disease · 2024Article
- Imaging Markers in Genetic Forms of Parkinson's Disease.Brain sciences · 2023Review
- Perspective on the current state of the LRRK2 field.NPJ Parkinson's disease · 2023Review
- The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease.Movement disorders clinical practice · 2023Article
- The emerging postural instability phenotype in idiopathic Parkinson disease.NPJ Parkinson's disease · 2022Article
- Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease.NPJ Parkinson's disease · 2021Article
- Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.NPJ Parkinson's disease · 2021Review
- Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.Journal of neurology · 2021Article
- Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers.Journal of Parkinson's disease · 2021Article
- Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.Movement disorders : official journal of the Movement Disorder Society · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the LRRK2 and GBA genes are the most common inherited causes of Parkinson's disease (PD). Studies exploring phenotypic differences based on genetic status used hypothesis-driven data-gathering and statistical-analyses focusing on specific symptoms, which may influence the validity of the results. We aimed to explore phenotypic expression in idiopathic PD (iPD) patients, G2019S-LRRK2-PD, and GBA-PD using a data-driven approach, allowing screening of large numbers of features while controlling selection bias. Data was collected from 1525 Ashkenazi Jews diagnosed with PD from the Tel-Aviv Medical center; 161 G2019S-LRRK2-PD, 222 GBA-PD, and 1142 iPD (no G2019S-LRRK2 or any of the 7 AJ GBA mutations tested). Data included 771 measures: demographics, cognitive, physical and neurological functions, performance-based measures, and non-motor symptoms. The association of the genotypes with each of the measures was tested while accounting for age at motor symptoms onset, gender, and disease duration;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.